HIV Infection

single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody

P2G12 Dose Cohort 1

single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody

P2G12 Dose Cohort 2

single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody

P2G12 Dose Cohort 3

St George's NHS Healthcare Trust

Study of Single IV Administration of P2G12

Phase I Dose Escalation Trial to Evaluate Safety and Reactogenicity of Single IV Administration of P2G12

St George's, University of London

Chronic Respiratory Diseases

Relative prevalence of different chronic respiratory disease phenotypes

epidemiology

Pham Ngoc Thach Hospital

Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam

This will be measured by the percentage of each chronic respiratory diseases phenotype, according to the lung function test.

This will be measured by means of a questionnaire.

This will be measured by means of a questionnaire and lung function test

Total IgE number and specific IgE number if needed depending on each phenotype of chronic respiratory disease

Olivier Michel

Head of clinic

Brugmann University Hospital

Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.

Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.

Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.

Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.

Poisoning

We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.

Chlorphenamine and Ranitidine

Therapeutic IV administration of 1g paracetamol results in a plasma concentration of ~12 mg/l. To achieve a desired concentration of ~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.

Paracetamol

To achieve a local paracetamol concentration of ~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.

Clinical Research Facility, Royal Infirmary of Edinburgh

Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects

Gemma Watson

University of Edinburgh

NHS Lothian

Fluid Overload

Water Electrolyte Imbalance

Acid Base Imbalance

2 litres intravenous infusion in 60 minutes

Crystalloid

1 litre intravenous infusion over 30 minutes

Colloid

Brain and Body MRI Centre, University of Nottingham

The Effect of Crystalloids and Colloids on Visceral Blood Flow

The Effects of Balanced and Unbalanced Crystalloids and Colloids on Serum Biochemistry and Visceral Blood Flow: A Two Phase, Double Blind, Randomised Crossover Study

anaphylaxis/nikotin

Study of Single IV Administration of P2G12

Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam

Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects

The Effect of Crystalloids and Colloids on Visceral Blood Flow

Najkompletnija baza ljekovitog bilja potpomognuta naukom